UCSF
Auto Added by WPeMatico
Mission Bio raises $70 million to help scale its tech for improving the development of targeted cancer therapies
California-based startup Mission Bio has raised a new $70 million Series C funding round, led by Novo Growth and including participation from Soleus Capital and existing investors Mayfield, Cota and Agilent. Mission Bio will use the funding to scale its Tapestri Platform, which uses the company’s work in single-cell multi-omics technology to help optimize clinical trials for targeted, precision cancer therapies.
Mission Bio’s single-cell multi-omics platform is unique in the therapeutic industry. What it allows is the ability to zero in on a single cell, observing both genotype (fully genetic) and phenotype (observable traits influenced by genetics and other factors) impact resulting from use of various therapies during clinical trials. Mission’s Tapestri can detect both DNA and protein changes within the same single cell, which is key in determining effectiveness of targeted therapies because it can help rule out the effect of other factors not under control when analyzing in bulk (i.e. across groups of cells).
Founded in 2012 as a spin-out of research work conducted at UCSF, Mission Bio has raised a total of $120 million to date. The company’s tech has been used by a number of large pharmaceutical and therapeutic companies, including Agios, LabCorp and Onconova Therapeutics, as well as at cancer research centers including UCSF, Stanford and the Memorial Sloan Kettering Cancer Center.
In addition to helping with the optimization of clinical trials for treatments of blood cancers and tumors, Mission’s tech can be used to validate genome editing — a large potential market that could see a lot of growth over the next few years with the rise of CRISPR-based therapeutic applications.
Powered by WPeMatico
Acting as the data integrator between hospitals and digital health apps brings Redox $33 million
Investors have forked over $33 million in a new round of funding for Redox, hoping that the company can execute on its bid to serve as the link between healthcare providers and the technology companies bringing new digital services to market.
The financing comes just two months after Redox sealed a deal with Microsoft to act as the integration partner connecting Microsoft’s Teams product to electronic health records through the Fast Healthcare Interoperability Resources standard.
Redox sits at a critically important crossroads in the modern healthcare industry. Its founder, a former employee at the electronic health record software provider Epic, knows more than most about the central position that data occupies in U.S. healthcare at the moment.
“What we’re doing, we’re building the platform and connector to help health systems integrate with technologies in the cloud,” says chief executive, Luke Bonney.
Bonney served as a team lead in various divisions at Epic before launching Redox, and the Madison, Wis.-based company was crafted with the challenges other vendors faced when trying to integrate with legacy systems like the health record provider.
“The fundamental problem is helping a large health system use a third-party tool that they want to use,” says Bonney. And the biggest obstacle, he said, is finding a way to organize into a format that application developers can work with the data coming from healthcare providers.
Investors including RRE Ventures, Intermountain Ventures and .406 Ventures joined new investor Battery Ventures in financing the $33 million round. As part of the deal, Battery Ventures general partner Chelsea Stoner will take a seat on the company’s board.
Application developers pay for the number of integrations they have with a health system, and Redox enables them to connect through a standard application programming interface, according to the company.
Its approach allows secure messaging across any format associated with an organization’s electronic health record (EHR), the company said.
Redox works with more than 450 healthcare providers and hundreds of application developers, the company said.
High-profile healthcare networks that work with the company include AdventHealth, Atrium Health, Brigham & Women’s, Clarify Health, Cleveland Clinic, Geisinger, HCA, Healthgrades, Intermountain Healthcare, Invitae, Fitbit, Memorial Sloan Kettering, Microsoft, Ochsner, OSF HealthCare, PointClickCare, R1, ResMed, Stryker, UCSF, University of Pennsylvania and WellStar.
Powered by WPeMatico
A new study out from health startup Cardiogram and the University of California San Francisco (UCSF) suggests wearables like the Apple Watch, Fitbit and others are able to accurately detect common but serious conditions like hypertension and sleep apnea.